CHICAGO - GE HealthCare (NASDAQ: NASDAQ:GEHC) today announced the introduction of its new Voluson Signature ultrasound systems, the Voluson Signature 20 and 18. These systems are designed to enhance women's health diagnostics by integrating artificial intelligence (AI), advanced tools, and an ergonomic design to expedite exam processes for healthcare providers.
The new technology aims to provide clearer imaging and faster examination times, essential for addressing the increasing complexity of patient conditions and the current challenges posed by workforce shortages in healthcare.
The Voluson Signature series seeks to alleviate some of the pressures on clinicians, with 42% of healthcare professionals considering leaving the industry due to high demands and workforce shortages, as highlighted in GE HealthCare's Reimagining Better Health study. The series features AI-powered tools intended to streamline workflows and reduce the physical and cognitive load on clinicians.
Key innovations of the Voluson Signature 20 and 18 include the Hey Voluson™ feature for voice-activated system operation, SonoLyst for AI-assisted fetal anatomy identification and measurement, which can cut down the time for second-trimester exams by up to 40%. The systems also feature SonoPelvicFloor, which automates assessments of the pelvic floor, and Fibroid Mapping for standardized fibroid documentation. The fetalHS tool is designed to simplify fetal heart assessments, potentially reducing the time needed by up to 48%.
The integration of the Vscan Air CL wireless dual probe with these systems also allows for a more flexible workflow, enabling clinicians to move more freely without the hindrance of cables.
Gerald Seifriedsberger, general manager of Women's Health Ultrasound at GE HealthCare, emphasized that the new systems not only aim to improve workflow efficiency but also to enhance diagnostic accuracy, potentially leading to earlier detection of conditions and better patient outcomes.
The Voluson Signature ultrasound systems are part of GE HealthCare's ongoing efforts to advance medical technology for women's health.
The information in this article is based on a press release statement from GE HealthCare.
InvestingPro Insights
GE HealthCare (NASDAQ: GEHC), a prominent player in the Healthcare Equipment & Supplies industry, is enhancing women's health diagnostics with its new Voluson Signature ultrasound systems. With the company's recent advancements, it's worth noting the financial metrics that may interest investors. GE HealthCare has a market capitalization of $38.87 billion USD, underscoring its significant presence in the market. The firm's Price to Earnings (P/E) ratio stands at 28.15, reflecting investor sentiment about its earnings potential. Additionally, GE HealthCare has demonstrated revenue growth of 6.6% over the last twelve months as of Q4 2023, which could be indicative of its ability to innovate and grow amidst evolving healthcare demands.
InvestingPro Tips reveal that GE HealthCare is trading at a high Price / Book multiple of 5.48, which may suggest that the market values the company's assets favorably. Moreover, the company has shown a strong return over the last three months with a 15.87% price total return, which aligns with the company's introduction of the Voluson Signature series and its potential impact on the market. Investors interested in GE HealthCare's performance and future prospects can find additional InvestingPro Tips, with a total of 6 tips available, including an analysis of profitability and price movements over the last six months. For those looking to delve deeper into GE HealthCare's financials, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.